Phase 3 Heart Disease Trial, Recruiting NCT06364150 Sponsor: Seoul National Hospital Condition: Heart Disease
Back to Heart Disease

Phase 3 Heart Disease Trial, Recruiting

NCT06364150
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 19 to 80 years, either male or female
  • People who have been clinically diagnosed with a heart attack within the past 4 weeks before being enrolled in the trial
  • People who have had a successful procedure to open a blocked heart artery (resulting in good blood flow and less than 30% remaining blockage), where a specially coated stent and/or balloon was used during the procedure
  • People who are willing and able to sign a written consent form agreeing to participate

Who may not be able to join:

  • People with severe or uncontrolled heart failure (specifically, those classed as Killip grade 2 or higher, or whose heart pumping function is below 20%)
  • People with ongoing chest pain caused by reduced blood flow to the heart that has not been brought under control
  • People with an uncontrolled irregular heartbeat
  • People with an active cancer, or a cancer that has not been fully treated
  • People with an active infectious disease
  • People with uncontrolled blood or clotting disorders, including conditions that cause abnormal bleeding
  • People with a serious non-heart-related illness where life expectancy is estimated at one year or less from the time of enrolment
  • Women who are pregnant, currently breastfeeding, or who could become pregnant
  • People who are not willing to sign the written consent form
  • People with other conditions that trial review committees determine may make it difficult to follow the trial procedures (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hyun Jai Cho, MD, Seoul National University Hospital

Phone: +821024162406

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Seoul National Hospital
Registry
ClinicalTrials.gov
Start date
15 July 2024
Est. completion
1 May 2025

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Left ventricular systolic function

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov